Endocrine therapy of prostate cancer

Cancer Treat Res. 1998;94:69-87. doi: 10.1007/978-1-4615-6189-7_5.

Abstract

Endocrine therapy is effective treatment for patients with metastatic prostate cancer. Most patients will benefit from androgen withdrawal in terms of symptomatic relief and delay in progression of diseases. It does not, however, cure patients with metastatic prostate cancer. This finding emphasizes the need for the development of effective nonendocrine therapies.

Publication types

  • Review

MeSH terms

  • 5-alpha Reductase Inhibitors
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / radiotherapy
  • Adenocarcinoma / surgery
  • Aminoglutethimide / therapeutic use
  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Enzyme Inhibitors / therapeutic use
  • Estrogens / therapeutic use
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Ketoconazole / therapeutic use
  • Male
  • Neoplasm Metastasis
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / mortality
  • Neoplasms, Hormone-Dependent / radiotherapy
  • Neoplasms, Hormone-Dependent / surgery
  • Orchiectomy
  • Prognosis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / surgery
  • Receptors, LHRH / drug effects
  • Spironolactone / therapeutic use
  • Survival Analysis
  • Testosterone*

Substances

  • 5-alpha Reductase Inhibitors
  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Enzyme Inhibitors
  • Estrogens
  • Receptors, LHRH
  • Aminoglutethimide
  • Spironolactone
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Ketoconazole